Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchBebtelovimabBebtelovimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

Summary of COVID-19 bebtelovimab studies

Studies   Meta Analysis   Hide extended summaries

9,162 patient bebtelovimab early treatment PSM study: 57% lower mortality (p=0.14), 59% lower ICU admission (p=0.05), 56% lower hospitalization (p<0.0001), and 33% higher progression (p=0.001).
Retrospective 3,739 patients treated with bebteloviman in the USA and matched controls, showing lower mortality and hospitalization with treatment, but higher emergency department visits.

Apr 2023, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971223005258, https://c19p.org/molina2

754 patient bebtelovimab early treatment study: 86% lower mortality (p=0.25), 43% lower combined mortality/hospitalization (p=0.14), and 29% lower hospitalization (p=0.53).
Retrospective 377 outpatients in the USA and matched controls, showing lower hospitalization/mortality with bebtelovimab treatment, without statistical significance. Notably, none of the patients that died in the control group were hospitalized within 14 days (later hospitalization is not reported). There may be a difference in the populations in terms of propensity to receive SOC.

Oct 2022, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofac565/6775265, https://c19p.org/drydenpeterson2

2,182 patient bebtelovimab early treatment PSM study: 86% lower mortality (p=0.25), 25% lower combined mortality/hospitalization (p=0.31), and 11% lower hospitalization (p=0.78).
PSM retrospective 19,778 high-risk outpatients in the USA, showing no significant difference in outcomes with bebtelovimab treatment.

Apr 2023, PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279326, https://c19p.org/sridhara

2,571 patient bebtelovimab early treatment study: 20% lower combined mortality/hospitalization (p=0.65).
Retrospective 2,571 patients treated with mAbs in the USA, and 5,135 control patients, showing lower combined mortality/hospitalization for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and bebtelovimab, with statistical significance only for casirivimab/imdevimab.

Apr 2023, Annals of Internal Medicine, https://www.acpjournals.org/doi/10.7326/M22-1286, https://c19p.org/kipbt

714 patient bebtelovimab early treatment RCT: 25% faster recovery and 4% improved viral clearance (p<0.0001).
RCT showing improved viral clearance with bebtelovimab. Results refer to the placebo controlled portion of the trial.

Mar 2022, medRxiv, https://www.medrxiv.org/content/10.1101/2022.03.10.22272100, https://c19p.org/dougan2

380 patient bebtelovimab early treatment RCT: 36% improved viral clearance (p=0.07).
RCT with 127 bamlanivimab, etesevimab, and bebtelovimab patients, 125 bebtelovimab patients, and 128 control patients, showing no significant differences in hospitalization and mortality. Viral clearance was improved although not statistically significant. NCT04634409.

Feb 2022, Lilly, https://clinicaltrials.gov/ct2/show/NCT04634409, https://c19p.org/blaze4
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit